Kuanoniamine A
Kuanoniamine A is a pyridoacridine alkaloid and also an anticancer agent. Kuanoniamine A inhibits DNA synthesis, induces apoptosis, and regulates the cell cycle by reducing the proportion of cells in the G2/M phase. Kuanoniamine A inhibits the proliferation of human lymphocytes. Kuanoniamine A can be used in research related to breast cancer, glioma, non-small cell lung cancer, and melanoma.
For research use only. We do not sell to patients.
- CAS No.: 133401-10-2
- Formula: C16H7N3OS
- Molecular Weight:289.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Kuanoniamine A (48 h) potently inhibits the growth of MCF-7, MDA-MB-231, NCI-H460, SF-268, UACC-62, and MRC-5 cells with GI50 values ranging from 0.12 to 4.67 μM after 48 h of continuous exposure[1].
Kuanoniamine A (0.04-86.51 μM; 6, 12, 24, 48 h) potently inhibits DNA synthesis in MCF-7 cells, with a concentration-dependent effect that reduces thymidine incorporation by over 60% at 0.08 μM across 6, 12, 24, and 48 h exposure times[1].
Kuanoniamine A (0.04-86.51 μM; 6, 12, 24, 48 h) reduces MCF-7 cell viability in a time-dependent manner, decreasing viability to 70% at 0.04 μM after 6 h exposure, with more severe reductions after 24 and 48 h[1].
Kuanoniamine A (0.04-86.51 μM; 6, 12, 24, 48 h) reduces cellular protein content in MCF-7 cells in a time-dependent manner, with effects mirroring its impact on cell viability measured by the MTT assay[1].
Kuanoniamine A (0.34 μM; 24 h) reduces the proportion of MCF-7 cells in G2/M phase, accumulates cells in G1 phase, and decreases the S phase fraction relative to untreated control cells[1].
Kuanoniamine A (0.5-1.0 μM; 24 h) increases the number of apoptotic MCF-7 cells relative to untreated control cells[1].
Kuanoniamine A (0.5-2.5 μM; 24 h) reduces MCF-7 cell viability to ≥70% at 0.5 and 1.0 μM after 24 h, while 2.5 μM drastically reduces viability to 35.7%[1].
Kuanoniamine A (0.12-86.51 μM; 96 h) potently inhibits PHA-induced proliferation of human lymphocytes with an IC50 of 1.50 μM after 96 h of continuous exposure[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-7
-
Concentration:0.34 μM
-
Incubation Time:24 h
-
Result:Caused an extensive reduction in the fraction of cells in G2/M phase (5.71% vs.
12.17% in control), a corresponding accumulation of cells in G1 phase (81.41% vs.
70.04% in control), and a reduction in the S phase fraction (12.88% vs.
17.79% in control).
-
Cell Line:MCF-7
-
Concentration:0.5 and 1.0 μM
-
Incubation Time:24 h
-
Result:Increased the number of apoptotic cells; 0.5 μM treatment resulted in 6.19% apoptotic cells, and 1.0 μM treatment resulted in 7.2% apoptotic cells, compared to 1.41% in untreated control cells.
-
Cell Line:MCF-7
-
Concentration:0.5, 1 and 2.5 μM
-
Incubation Time:24 h
-
Result:Moderately reduced viability at 0.5 and 1.0 μM (≥70% viable cells), while 2.5 μM caused a drastic decrease in viability to 35.7%.
Chemical Information
-
CAS No. 133401-10-2
-
Molecular Weight 289.31
-
Formula C16H7N3OS
-
SMILES
O=C1C2=NC=3C=CC=CC3C=4C=CN=C(C=5N=CSC15)C24
-
Structure Classification
-
Initial Source
Oceanapia sagittaria
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Kuanoniamine A Related Classifications
HY-118713 Related Classifications
Powered by Bioz